KPV Peptide

Evidence

KPV peptide benefits: separating findings from claims

Claimed KPV benefits graded against the literature. Every finding is from cell or animal research; no human benefit has been established.

By the KPV Peptide editorial team · Last reviewed · Editorial review: approved by Ryan DeLauz (bulk sign-off in chat, 2026-11-11)

Short answer

No benefit of KPV has been demonstrated in humans. The effects behind most benefit claims are reductions in inflammation markers measured in cell cultures and rodent models. FDA’s 2026 review found no human studies of KPV by any route and called the evidence insufficient to evaluate effectiveness[FDA briefing 2026].

How to read KPV benefit claims

Benefit lists online usually restate laboratory findings as if they were human outcomes. Below, each common claim is traced to the studies behind it and labelled with the kind of evidence it rests on, using the grades on our methodology page. A finding in mice shows what happened in mice under those conditions. It does not show the same thing will happen in a person, at any amount.

Common KPV benefit claims, what studies actually measured, and evidence level
Common claimWhat studies measuredEvidence level
“Reduces gut inflammation”Lower colitis scores, cytokines or MPO in chemically induced rodent colitis; lower NF-κB in intestinal cell lines. [Dalmasso 2008][Kannengiesser 2008]Animal + cell
“Heals the gut lining”Formulated KPV (nanoparticles, hydrogels) measured mucosal and barrier markers in rodent colitis. These are formulation effects. [Laroui 2010][Xiao 2017]Animal (formulations)
“Anti-inflammatory”Lower NF-κB, IL-8 and eotaxin in airway cells; less neutrophil influx in mouse peritonitis; less ear swelling in mice. [Land 2012][Getting 2003][Hiltz 1989]Animal + cell
“Good for skin”Higher viability and lower IL-1β in keratinocytes exposed to particulate matter. No topical study in human volunteers. [Sung 2025]Cell
“Wound healing”Faster corneal re-epithelialisation in rabbits; a KPV hydrogel measured oral-mucosa repair in rats. [Bonfiglio 2006][Shao 2021]Animal
“Antimicrobial”Mixed. Some culture studies report killing of S. aureus; a 2018 study found no activity for Ac-KPV-NH2. [Cutuli 2000][Singh 2011][Songok 2018]Cell (conflicting)
“Weight / fat loss”One 2026 study measured adipocyte differentiation and weight gain in high-fat-diet mice; a HepG2 study measured lipid accumulation. [An 2026][Lee 2026]Animal + cell (single lab)
“Neuroprotective”Smaller lesion volume after one administration in a mouse brain-injury model; cytokine expression was unchanged. [Schaible 2013]Animal
Any benefit in peopleNo human study exists [FDA briefing 2026].None

Why animal results may not carry over

  • Induced disease. Colitis in these studies is caused by chemicals such as DSS or TNBS over days. Human chronic conditions differ in cause and course.
  • Formulations. Several positive gut studies tested KPV inside nanoparticles or hydrogels, sometimes with another drug. The result belongs to the formulation [Laroui 2010].
  • Exposure. No study has measured how much KPV reaches human blood or tissue, so animal and cell concentrations cannot be translated [FDA briefing 2026].
  • Endpoints. Most studies measured biomarkers (cytokines, MPO, NF-κB), not symptoms or function.

Frequently asked questions

What are the proven benefits of KPV peptide?

None in humans. No clinical study of KPV has been published, and FDA found no human use data by any route. The reported effects come from cell cultures and rodent models.

Is KPV peptide anti-inflammatory?

In laboratory and animal models, KPV lowered several inflammation readouts, such as NF-κB activation, cytokine levels and myeloperoxidase. Whether that happens in people has never been tested.

Where can I read KPV benefits and side effects together?

This page covers reported findings by evidence level; the side-effects page covers what is known and unknown about safety. Both draw on the same verified studies database.

References

  1. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. PubMed 18061177 · doi:10.1053/j.gastro.2007.10.026[Animal, grade C]
  2. Kannengiesser K, Maaser C, Heidemann J et al. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. PubMed 18092346 · doi:10.1002/ibd.20334[Animal, grade C]
  3. Laroui H, Dalmasso G, Nguyen HT et al. (2010). Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology. PubMed 19909746 · doi:10.1053/j.gastro.2009.11.003[Animal, grade C]
  4. Xiao B, Xu Z, Viennois E et al. (2017). Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther. PubMed 28143741 · doi:10.1016/j.ymthe.2016.11.020[Animal, grade C]
  5. Land SC (2012). Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol. PubMed 22837805[In vitro, grade D]
  6. Getting SJ, Schiöth HB, Perretti M (2003). Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. PubMed 12750433 · doi:10.1124/jpet.103.051623[Animal, grade C]
  7. Hiltz ME, Lipton JM (1989). Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB J. PubMed 2550304[Animal, grade C]
  8. Sung J, Ju SY, Park S et al. (2025). Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway. Tissue Cell. PubMed 40073467 · doi:10.1016/j.tice.2025.102837[In vitro, grade D]
  9. Bonfiglio V, Camillieri G, Avitabile T et al. (2006). Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide. Exp Eye Res. PubMed 16965771 · doi:10.1016/j.exer.2006.07.014[Animal, grade C]
  10. Shao W, Chen R, Lin G et al. (2021). In situ mucoadhesive hydrogel capturing tripeptide KPV: the anti-inflammatory, antibacterial and repairing effect on chemotherapy-induced oral mucositis. Biomater Sci. PubMed 34846053 · doi:10.1039/d1bm01466h[Animal, grade C]
  11. Cutuli M, Cristiani S, Lipton JM et al. (2000). Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol. PubMed 10670585 · doi:10.1002/jlb.67.2.233[In vitro, grade D]
  12. Singh M, Mukhopadhyay K (2011). C-terminal amino acids of alpha-melanocyte-stimulating hormone are requisite for its antibacterial activity against Staphylococcus aureus. Antimicrob Agents Chemother. PubMed 21282427 · doi:10.1128/AAC.00957-10[In vitro, grade D]
  13. Songok AC, Panta P, Doerrler WT et al. (2018). Structural modification of the tripeptide KPV by reductive "glycoalkylation" of the lysine residue. PLoS One. PubMed 29953505 · doi:10.1371/journal.pone.0199686[In vitro, grade D]
  14. An SH, Park JY, Lee SJ (2026). KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARγ signaling. Tissue Cell. PubMed 42585803 · doi:10.1016/j.tice.2026.103837[Animal, grade C]
  15. Lee JY, Lee J, Jung WK et al. (2026). Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells. Cytotechnology. PubMed 42064835 · doi:10.1007/s10616-026-00967-z[In vitro, grade D]
  16. Schaible EV, Steinsträßer A, Jahn-Eimermacher A et al. (2013). Single administration of tripeptide α-MSH(11-13) attenuates brain damage by reduced inflammation and apoptosis after experimental traumatic brain injury in mice. PLoS One. PubMed 23940690 · doi:10.1371/journal.pone.0071056[Animal, grade C]
  17. U.S. Food and Drug Administration, Pharmacy Compounding Advisory Committee (2026-07-23). FDA Briefing Document: KPV-Related Bulk Drug Substances (KPV (free base) and KPV acetate). Source[retrieved 2026-11-11]